Perceptive Advisors LLC Iveric Bio, Inc. Transaction History

Perceptive Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $8.71 Million - $13.2 Million	-332,000 Reduced 66.4%	168,000 $6.61 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $1.63 Million - $2.15 Million	-87,400 Reduced 14.88%	500,000 $12.2 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $7.7 Million - $10.7 Million	-446,769 Reduced 43.2%	587,400 $12.6 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $9.91 Million - $19.6 Million	-1,053,787 Reduced 50.47%	1,034,169 $18.6 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $28.6 Million - $59.3 Million	-3,137,459 Reduced 60.04%	2,087,956 $20.1 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $15.2 Million - $21.1 Million	-1,254,585 Reduced 19.36%	5,225,415 $87.9 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $13.7 Million - $18.6 Million	-991,798 Reduced 13.27%	6,480,000 $108 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $20.4 Million - $50.5 Million	2,886,286 Added 62.94%	7,471,798 $121 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $522,218 - $708,285	102,799 Added 2.29%	4,585,512 $28.3 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $5.66 Million - $7.67 Million	1,001,282 Added 28.76%	4,482,713 $31 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $6.44 Million - $13.9 Million	2,104,142 Added 152.77%	3,481,431 $17.8 Million
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $1.1 Million - $3.27 Million	387,000 Added 39.08%	1,377,289 $4.74 Million
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $920,968 - $8.5 Million	990,289 New	990,289 $8.5 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.